Marc Simon is a Cardiology physician affiliated with University of California, San Francisco. OpenAlex indexes 408 publications with 9,403 citations (h-index 50); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 Mission Bay Blvd S
San Francisco, CA 941432156
Telephone
415-353-3109Provider last certified this registry record 14 Oct 2021.
Clinical trials
- Oral CXA-10 in Pulmonary Arterial Hypertension
Sponsor: Gladwin, Mark, MD
- Metformin for Pulmonary Hypertension HFpEF
Sponsor: University of California, San Francisco
- Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
Sponsor: Aadi Bioscience, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202523 payments$16,248openpaymentsdata.cms.gov ↗
- Actelion Pharmaceuticals US, Inc.Program year20255 payments
- Chiesi USA, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2022 per NIH RePORTER. The latest:
- Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
University of California, San Francisco
FY2022$576,734R01AG058659 - Phase II Trial of Metformin for Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
University of California, San Francisco
FY2021$657,956R01AG058659
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial
The Lancet Respiratory Medicine
2024 - Research Opportunities in Autonomic Neural Mechanisms of Cardiopulmonary Regulation
JACC Basic to Translational Science
2022 - Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction
Journal of the American College of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”